Outcomes Research Is Alternative To Focus On Cost, AstraZeneca Exec Says
Executive Summary
The pharmaceutical industry must be actively involved in determining health care outcomes or risk having the focus remain solely on drug costs, AstraZeneca Strategic Planning & Business Development Director Kim Slocum said during the World Health Care Congress Jan. 27 in Washington, D.C
You may also be interested in...
Cost Effectiveness Standard: Drugs Should Be “Innocent Until Proven Guilty”
Policies governing evidence-based medicine should presume that new drugs or devices are cost effective until comparative studies prove otherwise, AstraZeneca Director-Strategic Planning & Business Development Kim Slocum said during an April 27 1"Drug & Device Dialogue" audio conference sponsored by F-D-C Reports and Polidais
Cost Effectiveness Standard: Drugs Should Be “Innocent Until Proven Guilty”
Policies governing evidence-based medicine should presume that new drugs or devices are cost effective until comparative studies prove otherwise, AstraZeneca Director-Strategic Planning & Business Development Kim Slocum said during an April 27 1"Drug & Device Dialogue" audio conference sponsored by F-D-C Reports and Polidais
PhRMA Adopts Outcomes Research Policy; Set For Cost-Effectiveness Debate
Government-supported health outcomes research must recognize the benefits of multiple treatment options, the Pharmaceutical Research & Manufacturers of America's principles on outcomes research say